<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cysteine: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cysteine: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Cysteine: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8890" href="/d/html/8890.html" rel="external">see "Cysteine: Drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F20452482"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Elcys</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1057611"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Nutritional Supplement</span></li></ul></div>
<div class="block don drugH1Div" id="F53462418"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="488053bd-b0af-440b-b9f4-a44d326f706d">Parenteral nutrition additive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition additive:</b> Added as a fixed ratio to crystalline amino acid solution; dosage will vary with the daily amino acid dosage:</p>
<p style="text-indent:-2em;margin-left:4em;">ASPEN recommendations: Term and Preterm Neonates: IV: 30 to 40 mg of cysteine hydrochloride per gram of amino acids; a dose as low as 20 mg of cysteine hydrochloride per gram of amino acids may be adequate and should be used in times of cysteine shortage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1','lexi-content-ref-26150106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1','lexi-content-ref-26150106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Product-specific dosing: Term and Preterm Neonates: IV:</p>
<p style="text-indent:-2em;margin-left:6em;">L-cysteine: 40 mg cysteine hydrochloride per gram of amino acids.</p>
<p style="text-indent:-2em;margin-left:6em;">Elcys: 22 mg cysteine hydrochloride per gram of amino acids.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F155949"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="488053bd-b0af-440b-b9f4-a44d326f706d">Parenteral nutrition additive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Parenteral nutrition additive:</b> Added as a fixed ratio to crystalline amino acid solution; dosage will vary with the daily amino acid dosage. <b>Note: </b>Correct severe fluid, electrolyte, and acid-base disorders prior to administration.</p>
<p style="text-indent:-2em;margin-left:4em;">ASPEN Recommendations: Infants: IV: 30 to 40 mg of cysteine hydrochloride per gram of amino acids; a dose as low as 20 mg of cysteine hydrochloride per gram of amino acids may be adequate and should be used in times of cysteine shortage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1','lexi-content-ref-26150106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1','lexi-content-ref-26150106'])">Ref</a></span>); current practice suggests supplementation should be continued through the first year of life; practice varies widely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Corkins.1','lexi-content-ref-15568296']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Corkins.1','lexi-content-ref-15568296'])">Ref</a></span>); consult institution-specific policies.</p>
<p style="text-indent:-2em;margin-left:4em;">Product-specific dosing:</p>
<p style="text-indent:-2em;margin-left:6em;">L-cysteine: Infants: IV: 40 mg cysteine hydrochloride per gram of amino acids.</p>
<p style="text-indent:-2em;margin-left:6em;">Elcys:</p>
<p style="text-indent:-2em;margin-left:8em;">Infants and Children ≤11 years: IV: 22 mg cysteine hydrochloride per gram of amino acids.</p>
<p style="text-indent:-2em;margin-left:8em;">Children ≥12 years and Adolescents: IV: 7 mg cysteine per gram of amino acids.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51090496"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; may require more frequent monitoring. Contains aluminum, which may accumulate in renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51090497"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; may require more frequent monitoring.</p></div>
<div class="block doa drugH1Div" id="F53322187"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8890" href="/d/html/8890.html" rel="external">see "Cysteine: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7f15f64c-3b7e-4ce1-8617-86c846d7fdfc">Component of parenteral nutrition</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Component of parenteral nutrition (Elcys): Note:</b> Correct severe fluid, electrolyte, and acid-base disorders prior to administration. Cysteine dose is based on recommended daily protein (as amino acid) requirement.</p>
<p style="text-indent:-2em;margin-left:4em;">Stable or critically ill patients: <b>IV:</b> 7 mg cysteine hydrochloride per gram of amino acids (equivalent to 4.8 mg cysteine per gram of amino acids).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F53322188"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; use with caution. Contains aluminum, which may accumulate in renal impairment.</p></div>
<div class="block doha drugH1Div" id="F53322189"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; may require more frequent monitoring.</p></div>
<div class="block adr drugH1Div" id="F155935"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Flushing</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Localized warm feeling</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Localized erythema</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Hyperammonemia, metabolic acidosis</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:2em;">Local: Infusion site reaction, injection site phlebitis, venous thrombosis at injection site</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F155943"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Known hypersensitivity to one or more amino acids or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">L-cysteine (generic): Additional contraindications: Hepatic coma; metabolic disorders involving impaired nitrogen utilization</p>
<p style="text-indent:-2em;margin-left:2em;">Elcys: Additional contraindications: Inborn errors of amino acid metabolism; pulmonary edema or acidosis due to low cardiac output</p></div>
<div class="block war drugH1Div" id="F155932"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatobiliary effects: Hepatobiliary disorders (eg, cholecystitis, cholelithiasis, cholestasis, cirrhosis, hepatic steatosis, fibrosis) may occur in patients without liver disease and may lead to hepatic failure. Increase in blood ammonia levels and hyperammonemia may also occur. Monitor liver function.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperammonemia: Asymptomatic hyperammonemia without overt liver dysfunction has been reported. Infants (birth to 2 years of age) are especially at risk. Monitor blood ammonia levels frequently in infants.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiac disease: Use with caution in patients with cardiac insufficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Hypertonic glucose solutions should be used with caution in patients with diabetes or prediabetic patients.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment. Use in this patient population may result in hyperammonemia, metabolic alkalosis, prerenal azotemia, serum amino acid imbalances, stupor, and coma. In addition, IV parenteral nutrition in patients with impaired hepatic function may result in an increase in BUN (a modest rise is expected during increased protein intake).</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; may require more frequent monitoring. IV parenteral nutrition in patients with impaired renal function will induce or augment an increase in BUN (a modest rise in BUN is to be expected during increased protein intake). Discontinue infusion, when clinically indicated, if BUN levels exceed normal postprandial limits and continue to rise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pulmonary disease: Use with caution in patients with pulmonary disease.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infants: Metabolic acidosis has occurred in infants related to the additional acid provided by the "hydrochloride" component of cysteine; each 160 mg of L-cysteine delivers 1 mmol of hydrochloride; patients receiving the typical dose of L-cysteine of 40 mg for every gram of protein receive an additional 0.5 to 1 mEq/kg/day of chloride. To balance the extra hydrochloride ions and prevent acidosis, the use of acetate salts of electrolytes may be necessary (Cochran 1988; Heird 1988; Laine 1991; Plogsted 2015).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aluminum: Contains aluminum; toxic aluminum concentrations may be seen with high doses, prolonged use, or renal impairment. Premature infants are at higher risk due to immature renal function and aluminum intake from other parenteral sources. Parenteral aluminum exposure of &gt;4 to 5 mcg/kg/day is associated with CNS and bone toxicity; tissue loading may occur at lower doses. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Precipitates: Periodically inspect solution, infusion set and catheter for precipitates. Pulmonary vascular precipitates causing pulmonary vascular emboli and pulmonary distress has been reported (some fatal). If signs of pulmonary distress occur, stop the infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Acetate: Use acetate-containing solutions with extreme caution in patients with respiratory or metabolic alkalosis and in conditions in which there is an increased level or an impaired utilization of acetate such as severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Administration: For central or peripheral IV administration; peripheral administration of nutrition is dependent upon osmolality of solution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Potassium: Use potassium-containing solutions with extreme caution, if at all, in patients with severe renal failure, hyperkalemia, and in conditions where potassium retention is present (eg, metabolic acidosis).</p>
<p style="text-indent:-2em;margin-left:4em;">• Sodium: Use sodium-containing solutions with extreme caution, if at all, in patients with severe renal impairment, heart failure, and conditions in which edema exists with sodium retention.</p></div>
<div class="block foc drugH1Div" id="F155939"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous, as hydrochloride [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Elcys: 50 mg/mL (10 mL)</p></div>
<div class="block geq drugH1Div" id="F155928"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323086"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Elcys Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg/mL (per mL): $11.36</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adip drugH1Div" id="F53565894"><span class="drugH1">Additional Information</span>
<p style="text-indent:0em;display:inline">Addition of cysteine to PN solutions enhances the solubility of calcium and phosphate by lowering the overall pH of the solution</p></div>
<div class="block admp drugH1Div" id="F52612472"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV infusion: Not for direct IV infusion; administer as a component of parenteral nutrition solution: Infuse parenteral nutrition solution at rate as directed. Ensure proper catheter/needle placement prior to and during infusion; avoid extravasation.</p></div>
<div class="block adm drugH1Div" id="F53322190"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Not for direct IV infusion; must be diluted and mixed in parenteral nutrition solutions. Administered as a component of peripheral or central parenteral nutrition. Central or peripheral administration of nutrition is dependent upon osmolality of the final solution; solutions with osmolarity ≥900 mOsm/L must be infused via central venous catheter. Ensure proper catheter/needle placement prior to and during infusion; avoid extravasation. May require use of inline filter (consult specific product labeling and/or individual institutional policies and procedures). Cysteine may be added to amino acid solution prior to further admixing with dextrose for parenteral nutrition. Refer to manufacturer's labeling for additional information.</p></div>
<div class="block sts drugH1Div" id="F3051363"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">L-cysteine (generic): Store at 15°C to 30°C (59°F to 86°F). Do not freeze. Use admixture immediately or within 1 hour of admixing or may be refrigerated and used within 24 hours of the time of admixing.</p>
<p style="text-indent:-2em;margin-left:2em;">Elcys: Store at 20°C to 25°C (68°F to 77°F); avoid excessive heat. Do not freeze. Once opened, limit use for admixing to ≤4 hours at 25°C (77°F). Use admixture immediately or may store refrigerated for up to 24 hours (must use admixture within 24 hours after removal from refrigeration). Protect from light. Discard any remaining admixture.</p></div>
<div class="block usep drugH1Div" id="F53566318"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">L-cysteine (generic): Additive to amino acid solutions to meet the nutritional requirements of patients requiring total parenteral nutrition (TPN) (FDA approved in infants)</p>
<p style="text-indent:-2em;margin-left:2em;">Elcys: Additive to amino acid solutions to meet the nutritional requirements of patients requiring TPN (FDA approved in infants); additive to amino acid solutions to meet the nutritional requirements of patients with severe liver disease who may have impaired enzymatic processes and require TPN (FDA approved in all ages)</p></div>
<div class="block pri drugH1Div" id="F14079852"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Cysteine is generally considered to be a nonessential amino acid in adults because it can be synthesized from methionine (an essential amino acid). The RDA for methionine + cysteine is increased in during pregnancy (IOM 2005).</p>
<p style="text-indent:0em;margin-top:2em;">Appropriate use as an additive to amino acid solutions in pregnant patients requiring parenteral nutrition is not expected to cause adverse maternal or fetal outcomes.</p></div>
<div class="block mopp drugH1Div" id="F53566319"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Fluid and electrolyte status, serum osmolarity, ammonia (measure frequently in patients ≤2 years of age), pH, acid-base balance, liver and kidney function tests, blood glucose, triglycerides (if adding lipid emulsion), cholesterol, coagulation parameters, serum proteins, growth curve, urine osmolarity, WBC, and blood culture as indicated. Monitor solution, infusion set, and catheter for precipitates.</p></div>
<div class="block pha drugH1Div" id="F155931"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Endogenous cysteine is an amino acid synthesized from methionine via the transulfuration pathway, and serves as a precursor substrate for both glutathione and taurine. Exogenous cysteine provides cysteine to the systemic circulation of patients requiring parenteral nutrition who cannot synthesize adequate quantities due to deficient or insufficient cystathionase activity.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58189265"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cisteina rivero</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Gan le shu</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Acetium | Cystein | L cystein</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Cisten</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Acetium</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Hythiol s.s. seiyaku | Hythiol sanken</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Blooming | Elgiton | Elropon | Gelustin | L-stin | Lc | Listin | Mimi-l</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Acetium</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Etium</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Cisteina rivero</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3133154">
<a name="3133154"></a>Cochran EB, Phelps SJ, Helms RA. Parenteral nutrition in pediatric patients. <i>Clin Pharm</i>. 1988;7(5):351-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cysteine-pediatric-drug-information/abstract-text/3133154/pubmed" id="3133154" target="_blank">3133154</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Corkins.1">
<a name="Corkins.1"></a>Corkins MR, Balint J, Bobo E, et al. <i>The A.S.P.E.N Pediatric Nutrition Support Core Curriculum</i>. Silver Spring: MD: American Society of Parenteral and Enteral Nutrition; 2015.</div>
</li>
<li>
<div class="reference">
                  Elcys (cysteine) [prescribing information]. Lenoir, NC: Exela Pharma Sciences, LLC; April 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3122162">
<a name="3122162"></a>Heird WC, Hay W, Helms RA, Storm MC, Kashyap S, Dell RB. Pediatric parenteral amino acid mixture in low birth weight infants. <i>Pediatrics</i>. 1988;81(1):41-50.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cysteine-pediatric-drug-information/abstract-text/3122162/pubmed" id="3122162" target="_blank">3122162</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-IOM.1">
<a name="IOM.1"></a>IOM (Institute of Medicine), <i>Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids (Macronutrients)</i>, Washington, DC: The National Academies Press, 2005.</div>
</li>
<li>
<div class="reference">
                  L-cysteine hydrochloride [prescribing information]. Princeton, NJ: Sandoz; August 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1908633">
<a name="1908633"></a>Laine L, Shulman RJ, Pitre D, Lifschitz CH, Adams J. Cysteine usage increases the need for acetate in neonates who receive total parenteral nutrition. <i>Am J Clin Nutr</i>. 1991;54(3):565-567. doi: 10.1093/ajcn/54.3.565.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cysteine-pediatric-drug-information/abstract-text/1908633/pubmed" id="1908633" target="_blank">1908633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15568296">
<a name="15568296"></a>Mirtallo J, Canada T, Johnson D, et al. Safe practices for parenteral nutrition. <i>JPEN J Parenter Enteral Nutr</i>. 2004;28(6):S39-S70.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cysteine-pediatric-drug-information/abstract-text/15568296/pubmed" id="15568296" target="_blank">15568296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26150106">
<a name="26150106"></a>Plogsted S, Cober P, Gura KM, et al. Parenteral nutrition L-cysteine product shortage considerations. <i>Nutr Clin Pract</i>. 2015;30(4):579-580. doi: 10.1177/0884533615593604.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/cysteine-pediatric-drug-information/abstract-text/26150106/pubmed" id="26150106" target="_blank">26150106</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13196 Version 125.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
